

REMARKS

Claims 1 to 30 as amended are present for purposes of prosecution.

Reconsideration of the rejection of this application is respectfully requested in view of the above amendments and the following remarks.

Applicants note with appreciation that Claims 15 to 19 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claims 1 to 14 and 20 to 30 are rejected under 35 U.S.C. 112, second paragraph. The Examiner objects to the definition of R₇ as including a "group capable of bioconversion to generate the free phenol structure". This phrase has now been deleted from the claims.

Claims 20, 21, 23 and 24 are rejected under 35 U.S.C. 112, first paragraph on the ground that the specification "does not reasonably provide enablement for prevention or inhibition of said diseases [those diseases as defined in Claim 21] or prevention, treatment or inhibition of thyroid cancer.

The claims have been amended to delete "prevention or inhibition of the above-mentioned disease states.


To expedite prosecution of this application, Claim 21 has been amended to delete treatment of thyroid cancer.

In view of the foregoing, it is submitted that Claims 1 to 14 and 20 to 30 overcome all formal objections and are in condition to allowance.

It is also submitted that Claims 15 to 19, which are dependent upon amended Claim 1 and Claim 3, are now in condition for allowance as well.

Thus, it is believed that all of the Claims 1 to 30 as now amended are in condition for allowance.

Respectfully submitted,



Burton Rodney
Attorney for Applicants
Reg. No. 22,076

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4336

Date: April 8, 2004